NASDAQ:COGT Cogent Biosciences Q2 2026 Earnings Results & Report $29.22 +1.08 (+3.82%) As of 01:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Cogent Biosciences beat analyst earnings expectations in its Q2 2026 results, released August 10, 2026. The company reported EPS of -$0.52 versus the -$0.5550 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 10, 2026TimeBefore Market OpensConference Call8:00 AM ET Cogent Biosciences EPS ResultsActual EPS-$0.52Consensus EPS -$0.5550Beat/MissBeat by +$0.0350One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCogent Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$0.00 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCogent Biosciences' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 2, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cogent Biosciences Q2 2026 Earnings FAQ Did Cogent Biosciences beat earnings estimates for Q2 2026? Cogent Biosciences (NASDAQ:COGT) reported earnings of -$0.52 per share for Q2 2026, beating the consensus estimate of -$0.5550. The report was announced on Monday, August 10, 2026. When is Cogent Biosciences' next earnings date? Cogent Biosciences' next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cogent Biosciences on the company's earnings history page. Cogent Biosciences Earnings HeadlinesCogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDASeptember 25, 2026 | finance.yahoo.comWill FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?September 24, 2026 | finance.yahoo.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.October 15 at 1:00 AM | Decentralized Masters (Ad)Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA AcceptanceSeptember 24, 2026 | finance.yahoo.comCogent's Bezuclastinib NDA Accepted For Advanced Systemic Mastocytosis; PDUFA Set For June 2027September 15, 2026 | rttnews.comCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)September 15, 2026 | globenewswire.comSee More Cogent Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cogent Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cogent Biosciences and other key companies, straight to your email. Email Address About Cogent BiosciencesCogent Biosciences (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. The company’s research programs are designed to selectively target disease-driving proteins while minimizing effects on healthy cells. Cogent’s lead product candidate is bezuclastinib, also known as CGT948, an oral, highly selective inhibitor of the KIT D816V mutation and other KIT alterations. The company is evaluating bezuclastinib in systemic mastocytosis, a disorder involving the abnormal growth and accumulation of mast cells, as well as in gastrointestinal stromal tumors (GIST) and other KIT-driven diseases. Cogent conducts research and clinical development activities in the United States and works with healthcare professionals, patients and research institutions through its clinical programs. The company is headquartered in Boulder, Colorado, and is led by Andrew Robbins, who serves as president and chief executive officer.View Cogent Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth Path Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
